Gilead puts a timely spotlight on HIV prevention in Latino communities with 'Ahorita Mismo' campaign - Fierce Pharma

Gilead is back with the latest iteration of its HIV prevention initiative Care for the Culture — this time with a focus on the Latino and Black communities. Launched on National Latino AIDS Awareness Day, the new campaign revolves around the slogan “Ahorita Mismo,” which means “Right now” in Spanish. It’s designed to reach Latino and Black communities, specifically men who have sex with men — a group still disproportionately affected by HIV.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.